CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone–releasing hormone (GHRH) engineered to extend its half-life and duration of activity in research settings. The DAC modification allows the peptide to bind to circulating proteins, resulting in prolonged systemic exposure compared to non-DAC versions.

Preclinical and clinical research suggests that CJC-1295 w/ DAC may stimulate sustained activation of GHRH receptors in the anterior pituitary, supporting extended endogenous growth hormone release. These mechanisms are believed to influence downstream signaling pathways involving insulin-like growth factor-1 (IGF-1), metabolic regulation, and tissue-associated repair processes. Unlike exogenous growth hormone administration, this peptide has been studied for its ability to enhance physiologic hormone secretion patterns over a longer duration.

Beyond growth hormone dynamics, CJC-1295 w/ DAC has been investigated for its potential role in supporting metabolic balance, recovery-related signaling, and endocrine system regulation in controlled study environments. Ongoing research continues to evaluate its impact on hormonal modulation, protein synthesis pathways, and adaptive physiological responses.